Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-10-27 | 2025-08-29 |
| Drug Identification Number | 02347393 | 02347393 |
| Brand name | MENVEO | MENVEO |
| Common or Proper name | Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM-197 Conjugate Vaccine | Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM-197 Conjugate Vaccine |
| Company Name | GLAXOSMITHKLINE INC | GLAXOSMITHKLINE INC |
| Ingredients | CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP C OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE | CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP C OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE |
| Strength(s) | 47MCG 5MCG 5MCG 10MCG 5MCG | 47MCG 5MCG 5MCG 10MCG 5MCG |
| Dosage form(s) | POWDER FOR SOLUTION SOLUTION | POWDER FOR SOLUTION SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 1's | 1's |
| ATC code | J07AH | J07AH |
| ATC description | BACTERIAL VACCINES | BACTERIAL VACCINES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-09-08 | 2025-09-08 |
| Actual start date | 2025-09-08 | |
| Estimated end date | 2025-10-27 | 2025-10-16 |
| Actual end date | 2025-10-24 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Doses reserved for Public programs, supply disruptions may be seen in the private market. | Doses reserved for Public programs, supply disruptions may be seen in the private market. |
| Health Canada comments |